Bayer AG
Pharmaceuticals / Life Sciences / AgricultureFounded 1863- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
Bayer AG
Financial Performance
Last reviewed: July 2025 · By Swet Parvadiya
Revenue
$50.8B
Market Cap
$38.7B
Employees
92,815
Bayer paid $63 billion for Monsanto in 2018 and inherited what may be the most expensive litigation liability in corporate history. Within months of closing, a California jury awarded $289 million to a school groundskeeper who claimed Roundup caused his non-Hodgkin's lymphoma. Bayer AG is a German multinational life sciences company headquartered in Leverkusen, generating $50.8 billion in revenue in FY2024 across three segments: Pharmaceuticals, Consumer Health, and Crop Science. Revenue of $50.8 billion in FY2024 is essentially flat compared to $51.9 billion in 2023 and $50.7 billion in 2022, with FY2025 dropping slightly to approximately $49.5 billion. Net loss of -$2.55 billion in FY2024 reflects impairment charges, Roundup litigation provisions, and the restructuring costs of the Dynamic Shared Ownership program — not a collapse in underlying operating performance, but not profitable either. Both are on trajectories that suggest they can become multi-billion dollar franchises, which matters because Xarelto generates roughly $6 billion globally and its US exclusivity is finite. The Dynamic Shared Ownership restructuring reduced costs but generated $705 million in corn seed impairment reversals and similar agricultural reversals in 2025 — accounting outcomes that improve reported earnings without representing genuine business improvement.
Revenue Trend Analysis
YoY Change
-2.6%
3-Year CAGR
-0.8%
Peak Year
2023
Trend
Declining Trend
Bayer AG has reported revenue across 4 fiscal years, compounding at -0.8% annually over 3 years. The most recent year saw a 2.6% decline versus the prior year. Revenue peaked in 2023 at $51.9B. Out of 3 reported periods, 1 showed growth and 2 showed a decline.
| Fiscal Year | Revenue | YoY Change |
|---|---|---|
| FY2025 | $49.5B | -2.6% |
| FY2024 | $50.8B | -2.1% |
| FY2023 | $51.9B | +2.4% |
| FY2022 | $50.7B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Bayer reported a net loss of €2.5 billion despite €50.8 billion in revenue primarily because the company accrues ongoing Roundup litigation charges — €2-4 billion annually for settlements — plus €4.5 billion in non-cash amortisation of acquired intangibles from the Monsanto acquisition and €2+ billion in restructuring charges from DSO transformation. Core EBITDA before these items runs €12-13 billion (25% margin), reflecting healthy underlying business economics, but the reported loss creates a misleading picture of profitability. The gap between core EBITDA and net income — approximately €15 billion in 2023 — is the financial scar of the Monsanto acquisition's legacy liabilities, and until glyphosate litigation is fully resolved (if ever), GAAP net income will likely remain negative or near-zero.
Bayer faces potential Roundup/glyphosate litigation exposure estimated at $20+ billion beyond the $10.9 billion settlement paid in 2020, with 50,000+ remaining claims in the US and ongoing trial losses in state courts where juries award $1 billion+ punitive damages. Bayer's 2020 settlement was premised on EPA's finding that glyphosate is 'not likely to be carcinogenic' providing future protection, but courts have rejected this shield and continued awarding damages. The Ninth Circuit ruling in 2022 that required warning labels — contrary to EPA guidance — potentially opened millions of future claims from users exposed to glyphosate without cancer warnings. The uncertainty has forced Bayer to maintain an open-ended legal reserve, and analysts model €20-50 billion in total ultimate costs — approaching the €63 billion acquisition price itself.
The Monsanto acquisition increased Bayer's net debt from €18 billion to €36 billion (3.1x EBITDA), and combined with ongoing litigation charges, pushed Bayer to the precipice of credit downgrades that would have increased funding costs. Rating agencies S&P and Moody's cut Bayer's credit rating to BBB/Baa2 (one notch above non-investment-grade) in 2019, and management implemented asset sales — including Consumer Health partial IPO discussions and non-core divestitures — to reduce leverage. The debt load costs Bayer €1.5+ billion in annual interest, and the combination of debt service, litigation charges, and restructuring costs explains why Bayer's stock trades at 7-8x earnings versus pharmaceutical peers at 14-16x, reflecting the extraordinary uncertainty premium investors demand.
Bayer must replace €7+ billion in revenues from Xarelto and Eylea patent expirations by 2028 through pipeline drugs including Nubeqa (darolutamide, prostate cancer, $1B+ potential), kerendia (finerenone, kidney disease, $2B+ potential), and cell and gene therapy investments through Asklepios Biopharmaceuticals partnership. The pipeline requires €6.5 billion annual R&D spending (13% of revenue), and Bayer's pharmaceutical pipeline depth is adequate but not exceptional compared to AstraZeneca or Novo Nordisk who have breakthrough assets in high-growth categories. The pipeline investment timing — needing to succeed while managing Monsanto litigation and DSO transformation simultaneously — creates execution complexity that makes drug development timelines especially critical for Bayer's financial recovery.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Bayer AG Revenue & Financials." CorpDigest, https://corpdigest.com/company/bayer/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Bayer AG reported $50B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/bayer/financials" target="_blank" rel="noopener">CorpDigest — Bayer AG financials</a></div>